Delivery Order SPE2DB24D2101-SPE2DB25FKPTX
- Not listed
- The Defense Logistics Agency awarded a $3,268.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Linzess 290 micrograms capsules (30-unit pack) on May 27, 2025, with completion scheduled for May 28, 2025. The contract is unset-aside and competitively awarded, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.80 to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency (DLA) awarded a $3,061.96 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 micrograms capsules (30-count units) on September 9, 2025, with completion targeted for September 10, 2025. This firm fixed price contract represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The award supports the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,423.44 to supply Linzess 72 microgram capsules (30-count units) under a firm fixed price contract. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive, non-set-aside delivery order. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $3,795.86 delivery order to AmerisourceBergen Drug Corp for LINZESS 290 microgram capsules (30-count units) on August 6, 2025, with ultimate completion by August 7, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,072.79 to supply Linzess 290 microgram capsules (30-count units) under a firm fixed price contract. The delivery order, issued September 5, 2025, with an ultimate completion date of September 8, 2025, represents a small-value pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a $3,410.04 delivery order to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count unit of use packaging) with an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with the...
- The Defense Logistics Agency awarded a delivery order valued at $1,275.03 to AmerisourceBergen Drug Corp for the supply of Linzess 290 MCG capsules (quantity: 30-count unit) on April 24, 2025, with an ultimate completion date of April 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Linzess 145 microgram capsules (30-count units) valued at $9,140.32. This is a firm fixed-price, competitive delivery order with no set-aside designation and an ultimate completion date of September 15, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPTXDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count unit) valued at $1,153.75, with performance based in Conshohocken, Pennsylvania. This competitive, non-set-aside delivery order utilizes firm fixed pricing and is scheduled for completion by September 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and maintains extensive contracts with the Defense Logistics Agency to support military and veteran healthcare systems. This delivery order represents a continuation of services under AmerisourceBergen Drug Corp's larger relationship with the DLA, including its substantial Indefinite Delivery Contract (IDC) valued at $999,999,999 through December 2026, which provides comprehensive pharmaceutical and medical supply support to military healthcare programs worldwide. The company's federal portfolio demonstrates expertise in delivering a wide range of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies to support Defense Health Agency operations and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/19/25 |